A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
Titel:
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
Auteur:
Zinzani, P.L. Tani, M. Pulsoni, A. De Renzo, A. Stefoni, V. Broccoli, A. Montini, G.C. Fina, M. Pellegrini, C. Gandolfi, L. Cavalieri, E. Torelli, F. Scopinaro, F. Argnani, L. Quirini, F. Derenzini, E. Rossi, M. Pileri, S. Fanti, S. Baccarani, M.